Filing Details

Accession Number:
0001209191-17-035163
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-05-24 20:05:00
Reporting Period:
2017-05-22
Filing Date:
2017-05-24
Accepted Time:
2017-05-24 20:05:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1560241 G1 Therapeutics Inc. GTHX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1033409 N Fredric Eshelman C/o G1 Therapeutics, Inc.
79 T.w. Alexander Drive
Research Triangle Park NC 27709
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-05-22 3,139,151 $0.00 3,139,151 No 4 C Indirect See Footnote
Common Stock Acquisiton 2017-05-22 300,000 $15.00 3,439,151 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2017-05-22 6,893,224 $0.00 2,297,740 $0.00
Common Stock Series C Preferred Stock Disposition 2017-05-22 2,524,233 $0.00 841,411 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series B Preferred Stock and the Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.
  2. Eshelman Ventures, LLC is the record holder of the securities. Dr. Fredric Eshelman is the founder and principal of Eshelman Ventures, LLC and may be deemed to beneficially own the securities held by Eshelman Ventures, LLC. Dr. Eshelman disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
  3. Reflects shares Eshelman Ventures, LLC purchased in the initial public offering at the initial public offering price of $15.00 per share.
  4. The Series B Preferred Stock and the Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.